Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

345830 Galectin-3, Human, Recombinant, E. coli

345830
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Products

Katalogové čísloBalení ks/bal.
345830-100UG Plastová ampulka 100 μg
Description
OverviewRecombinant, human galectin-3 expressed in E. coli. Galectin-3 is a member of the β-galactoside-binding animal lectins. It has been implicated to be involved in various immunological processes, pre-mRNA splicing, cell adhesion, and tumor invasion. Levels of galectin-3 have been reported to be elevated in several metastatic cancers.
Catalogue Number345830
Brand Family Calbiochem®
SynonymsCBP30, CBP35, εBP, L-29, L-34, Mac-2
References
ReferencesLegendre, H., et al. 2003. Mod. Pathol. 16, 491.
Maeda, M., et al. 2003. J. Biol. Chem. 278, 18938.
Stock, M., et al. 2003. J. Biol. Chem. 278, 17360.
Hirabayashi, J., et al. 2002. Biochim. Biophys. Acta 1572, 232.
Iurisci, I., et al. 2000. Clin. Cancer Res. 6, 1389.
Oda, Y., et al. 1991. Gene 99, 279.
Product Information
FormLyophilized
FormulationLyophilized from diH₂O.
Quality LevelMQ100
Applications
Biological Information
Purity≥95% by SDS-PAGE
Physicochemical Information
ContaminantsEndotoxin: ≤1.0 EU/µg galectin-3
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution refrigerate (4°C). Stock solutions containing lactose are stable for up to 6 months at 4°C. Following dialysis and removal of lactose, stock solutions are stable for up to 4 days at 4°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
345830-100UG 04055977214338

Documentation

Galectin-3, Human, Recombinant, E. coli MSDS

Title

Safety Data Sheet (SDS) 

Galectin-3, Human, Recombinant, E. coli Certificates of Analysis

TitleLot Number
345830

References

Přehled odkazů
Legendre, H., et al. 2003. Mod. Pathol. 16, 491.
Maeda, M., et al. 2003. J. Biol. Chem. 278, 18938.
Stock, M., et al. 2003. J. Biol. Chem. 278, 17360.
Hirabayashi, J., et al. 2002. Biochim. Biophys. Acta 1572, 232.
Iurisci, I., et al. 2000. Clin. Cancer Res. 6, 1389.
Oda, Y., et al. 1991. Gene 99, 279.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision30-June-2008 RFH
SynonymsCBP30, CBP35, εBP, L-29, L-34, Mac-2
DescriptionRecombinant, human galectin-3 expressed in and purified from E. coli. Galectin-3 is a member of the β-galactoside-binding animal lectins. It has been implicated to be involved in various immunological processes, pre-mRNA splicing, cell adhesion, and tumor invasion. Levels of galectin-3 have been reported to be elevated in several metastatic cancers.
FormLyophilized
FormulationLyophilized from diH₂O.
Purity≥95% by SDS-PAGE
ContaminantsEndotoxin: ≤1.0 EU/µg galectin-3
SolubilityReconstitute in sterile PBS. For use in carbohydrate binding studies, lactose should be removed by dialysis.
Storage Avoid freeze/thaw
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution refrigerate (4°C). Stock solutions containing lactose are stable for up to 6 months at 4°C. Following dialysis and removal of lactose, stock solutions are stable for up to 4 days at 4°C.
Toxicity Standard Handling
ReferencesLegendre, H., et al. 2003. Mod. Pathol. 16, 491.
Maeda, M., et al. 2003. J. Biol. Chem. 278, 18938.
Stock, M., et al. 2003. J. Biol. Chem. 278, 17360.
Hirabayashi, J., et al. 2002. Biochim. Biophys. Acta 1572, 232.
Iurisci, I., et al. 2000. Clin. Cancer Res. 6, 1389.
Oda, Y., et al. 1991. Gene 99, 279.